94% of researchers rate our articles as excellent or good
Learn more about the work of our research integrity team to safeguard the quality of each article we publish.
Find out more
REVIEW article
Front. Pharmacol.
Sec. Pharmacology of Infectious Diseases
Volume 16 - 2025 | doi: 10.3389/fphar.2025.1528568
This article is part of the Research Topic Natural Products and Nanotechnology: Next-Generation Therapies for Infectious Diseases View all 4 articles
Towards the Elimination of Infectious HPV: Exploiting CRISPR/Cas Innovations
Provisionally accepted- 1 Jilin Medical University, Jilin, China
- 2 Second Affiliated Hospital of Jilin University, Changchun, Jilin Province, China
HPV has been conclusively associated with various human malignancies, making prevention and treatment strategies for HPV-induced diseases absolutely necessary. Currently, the primary prevention include HPV immunization and routine screening, which substantially reduce the risk of HPV prevalence. Nonetheless, for patients diagnosed with invasive, advanced, or recurrent malignancies, non-virus-specific therapies frequently lead to drug resistance and adverse effects, resulting in little to no significant improvement in treatment efficacy for numerous patients. Viral genome targeting therapy emerges as a potential avenue for the future management of HPV infections. As genetic modification technology rapidly advances, the CRISPR/Cas system has shown considerable promise in treating viral infections. Its capacity to selectively target and edit viral genomes for elimination positions it as a highly promising approach for combating HPV. The following review will explore the functions and applications of the CRISPR/Cas system as an innovative therapy for HPV. We will demonstrate the prospective efficacy of CRISPR/Cas as a groundbreaking and promising cure for HPV infections, while addressing both the opportunities and challenges associated with this novel approach.KEY WORDS：HPV，CRISPR/Cas，gene editing，viral genome targeting therapy，HPV-associated diseases
Keywords: HPV, CRiSPR/Cas, gene editing, viral genome targeting therapy, HPV-associated diseases
Received: 15 Nov 2024; Accepted: 07 Apr 2025.
Copyright: © 2025 Liu, Wang, Xu, Zhang, Qin, Liu, Jin and Zhao. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence:
Lianhai Jin, Jilin Medical University, Jilin, China
Donghai Zhao, Jilin Medical University, Jilin, China
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.